Login to Your Account



Clinic Roundup


Wednesday, September 14, 2011
ViroPharma Inc., of Exton, Pa., and Halozyme Therapeutics Inc., of San Diego, said ViroPharma started a Phase II study of a subcutaneous administration of Cinryze (C1 esterase inhibitor), in combination with Halozyme's Enhanze technology, in subjects with hereditary angioedema.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription